Biogen ownership
WebAbout Institutional Holdings. Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm, along with recent purchases and ... Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. See more Biogen was founded in 1978 in Geneva as Biotechnology Geneva by several prominent biologists, including Kenneth Murray from the University of Edinburgh, Phillip Allen Sharp from the Massachusetts Institute of Technology See more For the fiscal year 2024, Biogen reported earnings of US$2.539 billion, with an annual revenue of US$12.274 billion, an increase of 7.2% … See more In September 2024, Biogen agreed to pay $900 million to the U.S. federal governments, states, and a whistleblower who accused the company of paying kickbacks to doctors between 2009 and 2014 to increase prescriptions of Avonex, Tysabri, … See more Biogen focused its R&D efforts on the discovery and development of treatments for patients with high unmet medical needs in the areas of neurology, hematology, and immunology. See more • Neurological diseases • Kenneth Murray • Eisai • Tim Harris (biochemist) See more • Official website • Business data for Biogen Inc.: See more
Biogen ownership
Did you know?
WebSTATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Section 16. Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 ... determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested … WebFeb 11, 2024 · Every investor in Biogen Inc. (NASDAQ:BIIB) should be aware of the most powerful shareholder groups. We can see that institutions own the lion's share in the company with 88% ownership.
WebMar 27, 2024 · Review which funds and institutions currently hold Biogen Inc (BIIB:XNAS) stock for ownership information. WebApr 6, 2024 · As of April 6, 2024, the average one-year price target for Biogen is $327.50. The forecasts range from a low of $251.49 to a high of $407.40. The average price target represents an increase of 15. ...
Web104 rows · Apr 12, 2024 · During the previous two years, 1,245 institutional investors and hedge funds held shares of Biogen. The most heavily invested institutionals were … WebJun 28, 2024 · Under the terms of the 2012 joint venture agreement, Biogen will pay Samsung BioLogics approximately $700 million for the option shares, increasing …
WebJan 8, 2024 · A look at the shareholders of Biogen Inc. ( NASDAQ:BIIB) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are …
dibens leasing sa arr mercantil telefoneWebThe company's biotechnology services include offering therapies, clinical trials, research and development of treatment methods for the treatment of cold agglutinin disease, sickle cell disease and beta-thalassemia, enabling medical institutions and patients to get a wide range of scientific treatments to fight fatal blood diseases. dibens leasing s/a - arrendamento mercantilWebSep 16, 2024 · The general public holds a 13% stake in Biogen. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. citipower ctaWeb1 day ago · In September 2024, Humana filed a complaint that claimed Biogen developed a scheme to lure Medicare and its insurers to overpay for Tysabri, Avonex, and Tecfidera, … citipower distribution annual planning reportWebJan 8, 2024 · A look at the shareholders of Biogen Inc. (NASDAQ:BIIB) can tell us which group is most powerful.And the group that holds the biggest piece of the pie are institutions with 88% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company. citipower claimsWebBiogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, … citipower electronicsWebSangamo Therapeutics Stock Ownership FAQ. Who owns Sangamo Therapeutics? Sangamo Therapeutics (NASDAQ: SGMO) is owned by 61.61% institutional shareholders, 20.07% Sangamo Therapeutics insiders, and 18.32% retail investors. ... Biogen Inc's Sangamo Therapeutics shares are currently valued at $41.63M. citipower electricity